Key result
CTO revascularization linked to ~74% lower mortality in patients with elevated hsTn-I.
Why the study?
The survival benefit of revascularization of coronary chronic total occlusion remains controversial, leading authors to evaluate whether high-sensitivity troponin-I could identify patients who benefit from CTO revascularization.
Does CTO revascularization reduce all-cause mortality and adverse cardiovascular events in patients with stable coronary artery disease and elevated high sensitivity troponin-I levels?
Cohort (n=428)
Blinded adjudication of cause of death and follow-up collection
Yes
Does CTO revascularization reduce all-cause mortality and adverse cardiovascular events in patients with stable coronary artery disease and elevated high sensitivity troponin-I levels?
Baseline high-sensitivity troponin-I levels independently predict mortality in patients with coronary chronic total occlusions and may help identify the specific subgroup of patients with elevated ischemic burden who derive a survival benefit from CTO revascularization.
Answers are grounded in this paper and cite their sources.
May inform selective CTO decisions in elevated hsTn-I; leaves open causal benefit pending randomized confirmation.
Background The survival benefit of revascularization of chronic total occlusion (CTO) of the coronary arteries remains a subject of controversy. We measured high sensitivity troponin‐I (hsTn‐I) levels as an estimate of myocardial ischemia in patients with stable coronary artery disease, with the hypothesis that (1) patients with CTO have higher levels of hsTn‐I than patients without CTO, (2) hsTn‐I levels will predict adverse cardiovascular events in patients with CTO, and (3) patients with elevated hsTn‐I levels will have a survival benefit from CTO revascularization. Methods and Results In 428 patients with stable coronary artery disease and CTO undergoing coronary angiography, adverse event rates were investigated. Cox proportional hazards models and Fine and Gray subdistribution hazard models were performed to determine the association between hsTn‐I level and incident event rates in patients with CTO. HsTn‐I levels were higher in patients with compared with those without CTO (median 6.7 versus 5.6 ng/L, P =0.002). An elevated hsTn‐I level was associated with higher adverse event rates (adjusted all‐cause mortality hazard ratio, 1.19 [95% CI, 1.08–1.32]; P =0.030) for every doubling of hsTn‐I level. CTO revascularization was performed in 28.3% of patients. In patients with a high (>median) hsTn‐I level, CTO revascularization was associated with substantially lower all‐cause mortality (adjusted hazard ratio, 0.26 [95% CI, 0.08–0.88]; P =0.030) compared with those who did not undergo revascularization. In patients with a low ( < median) hsTn‐I level, event rates were similar in those with and without CTO revascularization. Conclusions HsTn‐I levels may help identify individuals who benefit from CTO revascularization.
No takes yet. Share an insight, caveat, or question.
Gold et al. (2023) conducted a cohort in Stable coronary artery disease with chronic total occlusion (CTO) (n=428). CTO revascularization (PCI or CABG) in patients with high (>median 6.7 ng/L) hsTn-I levels vs. No CTO revascularization (medical management or non-CTO revascularization only) was evaluated on All-cause mortality in patients with high (>median 6.7 ng/L) hsTn-I level (HR 0.26, 95% CI 0.08-0.88, p=0.030). CTO revascularization in patients with elevated hsTn-I was associated with lower all-cause mortality compared with non-revascularization.
Synapse has enriched 10 related papers. Consider them for comparative context: